We recorded differences between treatment groups in simeprevir or telaprevir-related adverse events ( @ % -LSB- @/@ -RSB- in the simeprevir group vs @ % -LSB- @/@ -RSB- in the telaprevir group ) , serious adverse events ( @ % -LSB- @/@ -RSB- vs @ % -LSB- @/@ -RSB- ) , and adverse events leading to simeprevir or telaprevir discontinuation ( @ % -LSB- @/@ -RSB- vs @ % -LSB- @/@ -RSB- ) .